Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

2018 Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) Drug Analysis -

Research and Markets
Posted on: 15 Feb 18

The "Drug analysis: Opdivo" drug pipelines has been added to's offering.

Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T cells.

PD-1 and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation (CD)28 and B7 family. The B7 family cell surface molecules and the cytotoxic T-lymphocyte antigen 4 family both regulate complex signaling pathways that affect T-cell activation, tolerance, and immunopathology.

Blocking the interactions between PD-1 and its corresponding ligands prevents T-cell exhaustion in patients with cancer, allowing the T cells to combat the tumor via natural immune response mechanisms.

Product Profiles

  • Opdivo: Colorectal cancer (CRC)
  • Opdivo: Head and neck cancer
  • Opdivo: Hepatocellular carcinoma (HCC)
  • Opdivo: Bladder cancer
  • Opdivo: Glioblastoma (GBM)
  • Opdivo: Renal cell cancer (RCC)
  • Opdivo: Non-small cell lung cancer (NSCLC)
  • Opdivo: Gastric cancer
  • Opdivo: Melanoma

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 15/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.